Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (41419) 41419
Publication (3850) 3850
Book Review (1760) 1760
Book Chapter (259) 259
Conference Proceeding (65) 65
Magazine Article (37) 37
Dissertation (9) 9
Data Set (8) 8
Presentation (3) 3
Book / eBook (1) 1
Government Document (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
placebo-controlled trial (37926) 37926
humans (31588) 31588
double-blind (21389) 21389
index medicus (19689) 19689
female (12024) 12024
male (10981) 10981
adult (7473) 7473
pharmacology & pharmacy (7137) 7137
treatment outcome (7076) 7076
middle aged (6978) 6978
randomized controlled-trial (5555) 5555
aged (5145) 5145
animals (4899) 4899
clinical neurology (4828) 4828
psychiatry (4729) 4729
medicine, general & internal (4475) 4475
care and treatment (4048) 4048
efficacy (3741) 3741
randomized controlled trials as topic (3659) 3659
neurosciences (3457) 3457
risk factors (3400) 3400
drug therapy (3393) 3393
clinical trials (3027) 3027
double-blind method (3014) 3014
research (2891) 2891
quality-of-life (2857) 2857
adolescent (2822) 2822
health aspects (2693) 2693
therapy (2666) 2666
gastroenterology & hepatology (2656) 2656
immunology (2623) 2623
analysis (2560) 2560
medicine & public health (2487) 2487
child (2409) 2409
prevention (2229) 2229
clinical trials as topic (2107) 2107
abridged index medicus (2054) 2054
children (1983) 1983
safety (1966) 1966
drug therapy, combination (1957) 1957
rheumatology (1814) 1814
oncology (1804) 1804
internal medicine (1793) 1793
quality of life (1714) 1714
article (1705) 1705
review (1648) 1648
pediatrics (1639) 1639
time factors (1588) 1588
aged, 80 and over (1542) 1542
endocrinology & metabolism (1540) 1540
severity of illness index (1533) 1533
treatment (1488) 1488
young adult (1487) 1487
infectious diseases (1485) 1485
cardiac & cardiovascular systems (1460) 1460
dose-response relationship, drug (1452) 1452
pharmacotherapy (1448) 1448
diagnosis (1395) 1395
prospective studies (1382) 1382
multicenter (1357) 1357
dosage and administration (1356) 1356
surgery (1342) 1342
mortality (1321) 1321
studies (1304) 1304
usage (1283) 1283
follow-up studies (1271) 1271
depression (1269) 1269
disease (1266) 1266
pain (1262) 1262
multiple sclerosis (1238) 1238
medicine, research & experimental (1212) 1212
prevalence (1199) 1199
management (1195) 1195
pregnancy (1193) 1193
medical research (1192) 1192
neurology (1170) 1170
cancer (1130) 1130
nutrition & dietetics (1130) 1130
child, preschool (1127) 1127
inflammation (1113) 1113
rheumatoid-arthritis (1082) 1082
metaanalysis (1080) 1080
disease progression (1069) 1069
antidepressive agents - therapeutic use (1067) 1067
drug administration schedule (1061) 1061
patients (1059) 1059
follow-up (1058) 1058
dietary supplements (1056) 1056
infant (1043) 1043
clinical-trial (1038) 1038
meta-analysis (1035) 1035
risk (1024) 1024
retrospective studies (1017) 1017
evidence-based medicine (1016) 1016
probiotics (1016) 1016
allergy (1015) 1015
medicine (1008) 1008
randomized-trial (1008) 1008
antipsychotic agents - therapeutic use (1007) 1007
urology & nephrology (1001) 1001
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (39575) 39575
German (871) 871
French (555) 555
Spanish (285) 285
Russian (92) 92
Portuguese (49) 49
Polish (45) 45
Turkish (42) 42
Japanese (18) 18
Chinese (17) 17
Italian (13) 13
Korean (13) 13
Hungarian (12) 12
Czech (11) 11
Icelandic (3) 3
Croatian (2) 2
Danish (2) 2
Slovenian (2) 2
Dutch (1) 1
Serbian (1) 1
Slovak (1) 1
Welsh (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
by Mitsumoto, Hiroshi, Dr and Brooks, Benjamin R, MD and Silani, Vincenzo, MD
Lancet Neurology, The, ISSN 1474-4422, 2014, Volume 13, Issue 11, pp. 1127 - 1138
Summary Amyotrophic lateral sclerosis (ALS) is one of the most rapidly progressive neurodegenerative diseases of unknown cause. Riluzole is the only drug that... 
Neurology | THYROTROPIN-RELEASING-HORMONE | PHASE-III | RANDOMIZED SEQUENTIAL TRIAL | DOUBLE-BLIND | PRACTICE PARAMETER UPDATE | PLACEBO-CONTROLLED TRIAL | LITHIUM-CARBONATE | STEM-CELL TRANSPLANTATION | QUALITY STANDARDS SUBCOMMITTEE | CLINICAL NEUROLOGY | DISEASE PROGRESSION | Neuroprotective Agents - therapeutic use | Amyotrophic Lateral Sclerosis - therapy | Stem Cell Transplantation - standards | Humans | Amyotrophic Lateral Sclerosis - diagnosis | Riluzole - therapeutic use | Stem Cell Transplantation - trends | Randomized Controlled Trials as Topic - trends | Randomized Controlled Trials as Topic - standards | Clinical trials | Amyotrophic lateral sclerosis | Neurosciences | Riluzole | Stem cells | FDA approval | Pharmaceutical industry | Drug therapy | Rodents
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Randomisation to protect against selection bias in healthcare trials
by Odgaard-Jensen, Jan and Odgaard-Jensen, Jan and Vist, Gunn E and Vist, Gunn E and Timmer, Antje and Timmer, Antje and Kunz, Regina and Kunz, Regina and Akl, Elie A and Akl, Elie A and Schünemann, Holger and Schünemann, Holger and Briel, Matthias and Briel, Matthias and Nordmann, Alain J and Nordmann, Alain J and Pregno, Silvia and Pregno, Silvia and Oxman, Andrew D and Oxman, Andrew D
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2011, Volume 4, Issue 4, p. MR000012
Background Randomised trials use the play of chance to assign participants to comparison groups. The unpredictability of the process, if not subverted, should... 
DESIGN AFFECTS OUTCOMES | LOW-BACK-PAIN | Clinical Trials as Topic [methods; standards; statistics & numerical data] | Treatment Outcome | Random Allocation | STROKE REHABILITATION | Randomized Controlled Trials as Topic [methods; standards; statistics & numerical data] | Controlled Clinical Trials as Topic [methods; standards; statistics & numerical data] | META-REGRESSION ANALYSIS | MEDICINE, GENERAL & INTERNAL | HISTORICAL CONTROLS | CLINICAL-TRIALS | Selection Bias | ACUTE MYOCARDIAL-INFARCTION | PLACEBO-CONTROLLED TRIALS | EMPIRICAL-EVIDENCE | METHODOLOGICAL QUALITY | Controlled Clinical Trials as Topic - standards | Randomized Controlled Trials as Topic - statistics & numerical data | Clinical Trials as Topic - statistics & numerical data | Controlled Clinical Trials as Topic - methods | Randomized Controlled Trials as Topic - methods | Controlled Clinical Trials as Topic - statistics & numerical data | Clinical Trials as Topic - methods | Clinical Trials as Topic - standards | Randomized Controlled Trials as Topic - standards
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Single-center trials show larger treatment effects than multicenter trials: Evidence from a meta-epidemiologic study
by Dechartres, Agnes and Boutron, Isabelle and Trinquart, Ludovic and Charles, Pierre and Ravaud, Philippe
Annals of Internal Medicine, ISSN 0003-4819, 2011, Volume 155, Issue 1, pp. 39 - 52
Background: A recent study suggested that results of single-center trials are frequently contradicted when similar trials are performed in multicenter... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | OBSTRUCTIVE PULMONARY-DISEASE | PUBLICATION BIAS | RANDOMIZED-CONTROLLED-TRIALS | PLACEBO-CONTROLLED TRIALS | EMPIRICAL-EVIDENCE | PROTON PUMP INHIBITORS | CONTROLLED CLINICAL-TRIALS | METHODOLOGICAL QUALITY | ARTERY-DISEASE | Epidemiologic Research Design | Meta-Analysis as Topic | Sample Size | Bias | Humans | Sensitivity and Specificity | Treatment Outcome | Multicenter Studies as Topic - standards | Odds Ratio | Randomized Controlled Trials as Topic - standards | Clinical trials | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Clinical trials and late‐stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014
by Schneider, L. S and Mangialasche, F and Andreasen, N and Feldman, H and Giacobini, E and Jones, R and Mantua, V and Mecocci, P and Pani, L and Winblad, B and Kivipelto, M and Stockholms universitet and Centrum för forskning om äldre och åldrande (ARC), (tills m KI) and Samhällsvetenskapliga fakulteten
Journal of Internal Medicine, ISSN 0954-6820, 03/2014, Volume 275, Issue 3, pp. 251 - 283
The modern era of drug development for A lzheimer's disease began with the proposal of the cholinergic hypothesis of memory impairment and the 1984 research... 
clinical trial | drug development | treatment | dementia | lzheimer | Clinical trial | Treatment | Drug development | Alzheimer | Dementia | ACETYL-L-CARNITINE | RANDOMIZED CONTROLLED-TRIAL | MILD COGNITIVE IMPAIRMENT | MEDICINE, GENERAL & INTERNAL | NATIONAL INSTITUTE | DOUBLE-BLIND | A-BETA | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | CONTROLLED-RELEASE PHYSOSTIGMINE | ASSOCIATION WORKGROUPS | Alzheimer Disease - complications | Humans | Biomarkers - analysis | Alzheimer Disease - drug therapy | Nootropic Agents - therapeutic use | Medication Therapy Management | Drug Monitoring - methods | Dopamine Agents - therapeutic use | Randomized Controlled Trials as Topic | Memory Disorders - drug therapy | Memory Disorders - etiology | Alzheimer Disease - metabolism | Cholinesterase Inhibitors - therapeutic use | Memantine - therapeutic use | Practice Guidelines as Topic | Drugs | Clinical trials | Biological products | Drug therapy | Alzheimer's disease | Basic Medicine | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial
by van Vollenhoven, RF, Dr and Ernestam, S, MD and Geborek, P, MD and Petersson, IF, MD and Cöster, L, MD and Waltbrand, E, MD and Zickert, A, MD and Theander, J, MD and Thörner, Å, MD and Hellström, H, MD and Teleman, A, MD and Dackhammar, C, MD and Akre, F, MD and Forslind, K, MD and Ljung, L, MD and Oding, R, MD and Chatzidionysiou, A, MD and Wörnert, M, RN and Bratt, J, MD and Medicincentrum and Linköpings universitet and Institutionen för klinisk och experimentell medicin and Länskliniken för Reumatologi i Östergötland and Östergötlands Läns Landsting and Hälsouniversitetet and Reumatologi
Lancet, The, ISSN 0140-6736, 2009, Volume 374, Issue 9688, pp. 459 - 466
Summary Background New treatment strategies for early rheumatoid arthritis are evolving rapidly. We aimed to compare addition of conventional disease-modifying... 
Internal Medicine | 3 MEDICATIONS | MEDICINE, GENERAL & INTERNAL | NECROSIS-FACTOR | MONOTHERAPY | EFFICACY | COMBINATION THERAPY | DOUBLE-BLIND | VALIDATION | PLACEBO-CONTROLLED TRIAL | ETANERCEPT | COLLEGE-OF-RHEUMATOLOGY | Hydroxychloroquine - therapeutic use | Sulfasalazine - therapeutic use | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Male | Treatment Outcome | Methotrexate - therapeutic use | Infliximab | Arthritis, Rheumatoid - drug therapy | Adult | Female | Aged | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Antirheumatic Agents - therapeutic use | Studies | Data analysis | Rheumatoid arthritis | Rheumatology | Quality control | Clinical trials | Drug therapy | Patients | Recruitment | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effects of folic acid supplementation on overall and site-specific cancer incidence during the randomised trials: meta-analyses of data on 50 000 individuals
by Vollset, Stein Emil, Prof and Clarke, Robert, Dr and Lewington, Sarah, DPhil and Ebbing, Marta, MD and Halsey, Jim, BSc and Lonn, Eva, Prof and Armitage, Jane, Prof and Manson, JoAnn E, Prof and Hankey, Graeme J, Prof and Spence, J David, Prof and Galan, Pilar, MD and Bønaa, Kaare H, Prof and Jamison, Rex, Prof and Gaziano, J Michael, MD and Guarino, Peter, PhD and Baron, John A, Prof and Logan, Richard FA, Prof and Giovannucci, Edward L, Prof and den Heijer, Martin, MD and Ueland, Per M, Prof and Bennett, Derrick, PhD and Collins, Rory, Prof and Peto, Richard, Prof and B-Vitamin Treatment Trialists' Co and B-Vitamin Treatment Trialists' Collaboration
Lancet, The, ISSN 0140-6736, 2013, Volume 381, Issue 9871, pp. 1029 - 1036
Summary Background Some countries fortify flour with folic acid to prevent neural tube defects but others do not, partly because of concerns about possible... 
Internal Medicine | PERICONCEPTIONAL VITAMIN SUPPLEMENTATION | MEDICINE, GENERAL & INTERNAL | MYOCARDIAL-INFARCTION | RISK-FACTOR | NEURAL-TUBE DEFECTS | LOWERING HOMOCYSTEINE | FLOUR FORTIFICATION | CARDIOVASCULAR-DISEASE | PLACEBO-CONTROLLED TRIAL | B-VITAMINS | VASCULAR-DISEASE | Neoplasms - chemically induced | Folic Acid - adverse effects | Humans | Middle Aged | Female | Male | Dietary Supplements - adverse effects | Folic Acid - administration & dosage | Carcinogens - administration & dosage | Neoplasms - epidemiology | Incidence | Randomized Controlled Trials as Topic | Cardiovascular disease | Vitamin B | Mortality | Colorectal cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Effect of Anti-inflammatory Treatment on Depression, Depressive Symptoms, and Adverse Effects: A Systematic Review and Meta-analysis of Randomized Clinical Trials
by Köhler, Ole and Benros, Michael E and Nordentoft, Merete and Farkouh, Michael E and Iyengar, Rupa L and Mors, Ole and Krogh, Jesper
JAMA Psychiatry, ISSN 2168-622X, 12/2014, Volume 71, Issue 12, pp. 1381 - 1391
IMPORTANCE: Several studies have reported antidepressant effects of anti-inflammatory treatment; however, the results have been conflicting and detrimental... 
C-REACTIVE PROTEIN | PHASE-III TRIAL | SEROTONIN REUPTAKE INHIBITORS | PSYCHIATRY | DRUGS | DOUBLE-BLIND | SEVERE PSORIASIS | OPEN-LABEL | PLACEBO-CONTROLLED TRIAL | MAJOR DEPRESSION | ADJUNCTIVE THERAPY | Anti-Inflammatory Agents - therapeutic use | Depression - drug therapy | Anti-Inflammatory Agents - adverse effects | Humans | Randomized Controlled Trials as Topic | Usage | Care and treatment | Diagnosis | Anti-inflammatory drugs | Depression, Mental | Meta-analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The ADDITION-Cambridge trial protocol: A cluster Randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients
by Echouffo-Tcheugui, Justin B and Simmons, Rebecca K and Williams, Kate M and Barling, Roslyn S and Prevost, A Toby and Kinmonth, Ann Louise and Wareham, Nicholas J and Griffin, Simon J
BMC Public Health, ISSN 1471-2458, 2009, Volume 9, Issue 1, pp. 136 - 136
Background: The increasing prevalence of type 2 diabetes poses a major public health challenge. Population-based screening and early treatment for type 2... 
COST-EFFECTIVENESS | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | MULTIFACTORIAL INTERVENTION | CARDIOVASCULAR-DISEASE | GENERAL-PRACTICE | PHYSICAL-ACTIVITY | RISK SCORE | PLACEBO-CONTROLLED TRIAL | PSYCHOLOGICAL IMPACT | BLOOD-GLUCOSE CONTROL | UNDIAGNOSED HYPERGLYCEMIA | Mass Screening - economics | Humans | Middle Aged | Diabetes Mellitus, Type 2 - economics | Mass Screening - methods | Aspirin - administration & dosage | Diabetes Mellitus, Type 2 - diagnosis | Hypoglycemic Agents - administration & dosage | Cost-Benefit Analysis | Diabetes Mellitus, Type 2 - therapy | Sodium Chloride Symporter Inhibitors - administration & dosage | Adult | Anti-Inflammatory Agents - administration & dosage | Aged | Metformin - administration & dosage | Early Diagnosis | Type 2 diabetes | Medical research | Care and treatment | Usage | Prognosis | Medicine, Experimental | Diagnosis | Research | Cardiovascular diseases | Risk factors | Methods
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials
by Lytvyn, Yuliya and Bjornstad, Petter and Udell, Jacob A and Lovshin, Julie A and Cherney, David Z.I
Circulation, ISSN 0009-7322, 10/2017, Volume 136, Issue 17, pp. 1643 - 1658
Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are... 
Heart failure | Sodium glucose transporter 2 | Clinical trial | clinical trial | heart failure | RANDOMIZED CONTROLLED-TRIALS | CARDIAC & CARDIOVASCULAR SYSTEMS | SGLT2 INHIBITORS | CANAGLIFLOZIN CARDIOVASCULAR ASSESSMENT | PRESERVED EJECTION FRACTION | BLOOD-PRESSURE | BASE-LINE CHARACTERISTICS | sodium glucose transporter 2 | EVENT REPORTING SYSTEM | PERIPHERAL VASCULAR DISEASE | PLACEBO-CONTROLLED TRIAL | TYPE-2 DIABETES-MELLITUS | REG OUTCOME TRIAL | Diabetic Cardiomyopathies - metabolism | Diabetic Cardiomyopathies - drug therapy | Sodium-Glucose Transporter 2 - metabolism | Coronary Artery Disease - metabolism | Humans | Risk Factors | Hypertension - drug therapy | Male | Sodium-Glucose Transporter 2 Inhibitors | Clinical Trials as Topic | Heart Failure - metabolism | Hospitalization | Coronary Artery Disease - drug therapy | Diabetes Mellitus, Type 2 - metabolism | Heart Failure - drug therapy | Hypertension - metabolism | Benzhydryl Compounds - adverse effects | Female | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Glucosides - adverse effects | clinical trials review | SGLT2 inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights